Tau Positron Emission Tomography (PET) in Imaging and Cognition

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY

The investigators aim to use the new PET radioligand, 18F-MK-6240, to detect tau pathology in cognitive healthy and mild cognitive impairment (MCI) elders. The investigators will then examine the interactions between differential tau burden and performance on cognitive tasks, functional magnetic resonance imaging (fMRI) neural activation patterns, and other cognitive and behavioral measures. By investigating these relationships, the investigators hope to understand the cognitive and behavioral outcomes of tau deposition found in specific brain regions in cognitively normal/mildly cognitively impaired adults. Furthermore, the study aims to examine how the presence of tau may contribute to the risk of subsequent cognitive decline, neurodegeneration, and dementia.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 90
Healthy Volunteers: t
View:

• Aged 55-90

• Previously received an amyloid PET scan

• Residing near Columbia University Medical Center

• Must be willing and able to participate

Locations
United States
New York
Columbia University Medical Center
RECRUITING
New York
Contact Information
Primary
Reshma Babukutty
rb2996@cumc.columbia.edu
212-305-6314
Time Frame
Start Date: 2018-06-01
Estimated Completion Date: 2027-12
Participants
Target number of participants: 105
Treatments
Non-demented elders
Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
Related Therapeutic Areas
Sponsors
Leads: Yaakov Stern
Collaborators: National Institute on Aging (NIA)

This content was sourced from clinicaltrials.gov